The company expects revenue to grow in the mid to high single digits in FY26 but has not offered specific margin guidance for the year.

The company projects revenue growth of mid- to high single digits in FY26 compared with an 8.5% increase in FY25 ...

Clear signs of immune activation : ICT01 at the 10 mg dose provided optimal activation of γ9δ2 T cells and a downstream immune cascade, supporting its role in enhancing Aza-Ven efficacy, and ...

Dystrophic epidermolysis bullosa (DEB) is one of the main subtypes of epidermolysis bullosa, a group of genetic skin disorders characterized by varying degrees of fragility in the skin and mucous ...

The field of tumor immunology has highlighted the adeptness of tumor cells in evading the host's immune system. This insight has fueled interest in ...

Checkpoint Therapeutics Inc. defeated investor claims it concealed the likelihood US regulators would deny its skin cancer ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

Macquarie has reaffirmed its ‘outperform’ rating on Sun Pharmaceutical Industries Ltd. and raised its target price to Rs ...

A new generation of checkpoint inhibitors is emerging, with some showing more promise than others. From recent TIGIT failures ...

Q1 2025 Earnings Call Transcript May 15, 2025 Operator: Thank you for standing by. My name is Rochelle, and I will be your ...

Emrosi commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoin ...

BioNTech's BNT324 aims to outpace rivals in cancer treatment with its unique bispecific antibody design. Read more here.